Last updated: 6 months ago
InflaRx N.V. Financial Report: $30M Capital Raise via 6-K Filing
Explore InflaRx N.V.'s latest 6-K filing detailing a $30M capital raise, including offering specifics and underwriter agreements.
Posts for InflaRx N.V. ($IFRX)
Showing 1 - 3 of 3 Posts
Last updated: 7 months ago
InflaRx N.V. Secures EU Approval for GOHIBIC®: A Game Changer for ARDS Treatment
InflaRx N.V. announces EU marketing authorization for GOHIBIC® to treat SARS-CoV-2-induced ARDS, marking a significant milestone in respiratory care. Learn more about this groundbreaking approval.
Last updated: 8 months ago
InflaRx N.V. Report: Phase 2a Study for INF904 Dosing Begins!
InflaRx N.V. announces the first dosing in its Phase 2a study for INF904, targeting CSU and HS. Results expected in summer 2025. Key insights and strategies unveiled.